Free Research Report as Becton, Dickinson and Co.’s Revenues Surged 42.2%; Adjusted Earnings Soared 15.2%

Stock Monitor: Cantel Medical Post Earnings Reporting

LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free earnings report on Becton, Dickinson and Co. (NYSE: BDX) (“BD”), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BDX. The Company reported its financial results on May 03, 2018, for the second quarter of the fiscal year 2018 (Q2 FY18). The global medical technology Company surpassed market estimates for revenues and earnings for Q2 FY18. In addition, the Company also raised its guidance for the full fiscal year 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Cantel Medical Corp. (NYSE: CMD), which also belongs to the Healthcare sector as the Company Becton, Dickinson. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CMD

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Becton, Dickinson most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BDX

Earnings Highlights and Summary

For the second quarter of the fiscal year 2018, BD’s revenues advanced 42.2% to $4.22 billion compared to $2.97 billion in the second quarter of the fiscal year 2017, primarily due to the acquisition of C. R. Bard. The Company’s revenue numbers topped analysts’ estimates of $4.12 billion.

For the reported quarter, BD incurred total operating costs and expenses of $4.04 billion versus $2.52 billion in the year ago comparable period. The Company’s total costs included selling and administrative (S&A) expenses of $2.62 billion, and research and development (R&D) expenses of $1.06 billion in Q2 FY18 compared to $1.54 billion and $724.0 million, respectively, in Q2 FY17. The Company’s operating income declined to $183.0 million in the reported quarter compared to $446.0 million in the year ago corresponding period.

BD reported a net loss of $50.0 million in Q2 FY18 compared to a net income of $344.0 million in Q2 FY17, decreasing 114.5% on a y-o-y basis. For the reported quarter, the Company incurred a loss of $0.19 per share compared to an income of $1.58 per share in the year ago same period, primarily due to purchase accounting expenses related to acquisitions. The Company’s adjusted earnings per share (EPS) advanced 15.2% to $2.65 in Q2 FY18 compared to $2.30 in Q2 FY17, beating market projections of $2.61.

Segment Details

BD operates through three principal business segments, namely (i) BD Medical (“Medical”); (ii) BD Life Sciences (“Life Sciences”); and (iii) BD Interventional (“Interventional”).

During Q2 FY18, BD’s Medical segment generated total revenues of $2.17 billion compared to $1.82 billion in Q2 FY17, increasing 19.7% on a y-o-y basis. The segment’s positive results were driven by a favorable performance in its Medication Delivery Solutions, Diabetes Care, and Pharmaceutical Systems units. The segment’s operating income increased to $588.0 million in the reported quarter versus $475.0 million in the prior year’s comparable period.

For the reported quarter, BD’s Life Sciences segment’s total revenues improved 11.8% to $1.10 billion compared to $982.0 million in in prior year’s corresponding quarter, driven by a strong performance in its Diagnostic Systems and Biosciences units. The segment aggregated an operating income of $336.0 million in Q2 FY18 compared to $177.0 million in Q2 FY17.

BD’s Interventional segment added total revenues of $952.0 million in Q2 FY18 compared to $173.0 million in Q2 FY17. The segment incurred a net operating loss of $154.0 million in the reported quarter compared to a net income of $61.0 million in the same period of the prior fiscal year.

For the reported quarter, BD’s revenues from the United States grew by 42.9% to $2.33 billion versus $1.63 billion in the year ago comparable period. During Q2 FY18, the Company’s revenues from the International market increased 41.4% to $1.90 billion compared to $1.34 billion in Q2 FY17.

Cash Matters

As of March 31, 2018, BD’s cash and cash equivalents were $1.25 billion compared to $14.18 billion as of September 30, 2017. The Company had a long-term debt of $22.59 billion as of March 31, 2018, versus $18.67 billion as of September 30, 2017.

Outlook

For FY18, BD expects revenue growth to be in range of 5.0% to 5.5%, which is the high-end of its previous guidance range. The Company anticipates adjusted EPS to be in the band of $10.85 to $11.00, reflecting an improvement of approximately 15.0% to 16.0%.

Stock Performance Snapshot

June 04, 2018 – At Monday’s closing bell, Becton, Dickinson’s stock climbed 1.51%, ending the trading session at $228.33.

Volume traded for the day: 895.73 thousand shares.

Stock performance in the last month – up 0.53%; previous three-month period – up 5.09%; past twelve-month period – up 18.27%; and year-to-date – up 6.67%

After yesterday’s close, Becton, Dickinson’s market cap was at $61.04 billion.

Price to Earnings (P/E) ratio was at 314.07.

The stock has a dividend yield of 1.31%.

The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 501738